InMed Pharmaceuticals, Inc.

Pharmaceutical INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs Manufacturing BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing Investors News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Corporate Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Learn INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Pharmaceutical INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs Manufacturing BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing Investors News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Corporate Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Learn INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Vancouver, British Columbia–(Newsfile Corp. – February 12, 2025) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the second quarter of the fiscal year 2025 which ended December 31, 2024. The Company’s full financial statements and related MD&A for the first quarter ended December 31, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov. Eric A. Adams, InMed’s Chief Executive Officer, commented, “We are pleased with the steady progress across both our pharmaceutical pipeline and commercial operations. The compelling data from INM-901’s preclinical study demonstrated a significant reduction in neuroinflammatory markers-a key contributor to Alzheimer’s disease progression. This positions INM-901 as an innovative approach targeting neuroinflammation, extending beyond traditional amyloid beta and tau-focused therapies. Additionally, the selection of an intravitreal formulation for INM-089 marks a critical milestone in advancing our dry AMD program, offering new possibilities for treatment delivery.” Adams continued, “BayMedica continues to streamline its supply chain and reduce operational costs as it transitions to a profitable business unit, despite a challenging market landscape.” Business Update – Pharmaceutical Development Programs INM-901: Targeting multiple biological pathways in Alzheimer’s disease (‘AD’) INM-901 is a proprietary small molecule drug candidate with multiple mechanisms of action, currently in development as a potential treatment for AD. Recently the Company announced positive results from a long-term in vivo preclinical AD study. In the study, INM-901 demonstrated a reduction in several plasma and brain markers of neuroinflammation, a recognized contributor to AD development and progression. The ability of INM-901 to actively reduce inflammation is an exciting development, as neuroinflammation has emerged as a promising new drug target beyond existing AD treatments focused primarily on removing amyloid beta plaques and tau protein tangles. The Company is evaluating additional parameters from this long-term in vivo study and is conducting further molecular analyses to better define the mechanisms of action and potential role of INM-901 in AD treatment. The analyses will focus on the following areas via mRNA, protein and histological measurements: Receptor engagement levels: CB1/CB2 and PPAR; Neuritogenesis: assess markers for neuronal differentiation and neuronal function; and Neuroprotection: evaluating stress responses and cellular growth/survival. Receptor engagement levels: CB1/CB2 and PPAR; Neuritogenesis: assess markers for neuronal differentiation and neuronal function; and Neuroprotection: evaluating stress responses and cellular growth/survival. The Company is expected to report on these aspects of the study in the coming weeks. INM-089: Targeting the treatment of dry Age-related Macular Degeneration (“AMD”) INM-089 is a proprietary small molecule drug candidate being studied in the treatment of dry AMD. Recently, the Company announced the selection of an intravitreal (‘IVT’) formulation for INM-089 as a drug candidate to be utilized in the Company’s ongoing development program targeting the treatment of dry AMD. INM-089 can be successfully delivered as an IVT formulation, offering several advantages for the continued development of this compound in the treatment of dry AMD. Financial commentary: For the three months ended December 31, 2024, the Company reported a net loss of $2.6 million, compared to a net loss of $1.5 million in the same period the previous year. The increase was primarily driven by higher expenses related to pharmaceutical research and development activities, as well as financing costs. Pharmaceutical research and development and patent expenses were $1M for the three months ended December 31, 2024, compared with $0.6M for the three months ended December 31, 2023. The increase in research and development and patents expenses was due primarily to an increase in external contractors and patent fees offset by a decrease in compensation expenses. General and administrative expenses were $1.6M for the three months ended December 31, 2024, compared with $1.4M for the three months ended December 31, 2023. The increase results primarily from a combination of changes including higher consulting fees, legal fees and personnel expenses. This was offset by a decrease in lower office and administrative expenses. As of December 31, 2024, the Company’s cash, cash equivalents and short-term investments were $3.5M, which compares to $6.6M at June 30, 2024. The Company continues to closely monitor expenses while advancing its pharmaceutical pipeline candidates. Based on cash equivalents and short-term investments of $3.5 million as of December 31, 2024 and the receipt of $2.9M in gross proceeds from financing activities which took place in January 2025, the Company expects its cash will be sufficient to fund its planned operating expenses and capital expenditures through to the end of the second quarter of calendar year 2025, depending on the level and timing of BayMedica commercial revenues, as well as the level and timing of our operating expenses. BayMedica’s commercial business generated revenues of $1.1 million for the three months ended December 31, 2024, compared to $1.2 million for the same period last year, reflecting a 10% decrease. This decrease was primarily the result of the Company decrease was primarily the result of negative pricing variance during the period. Despite the decrease in revenues, BayMedica achieved a net income of $0.23M, representing a 189% improvement over the same period last year. This growth was primarily driven by a reduction in inventory write-downs and lower operational expenses in the current period compared to the same period last year, highlighting BayMedica’s continued progression as a profitable business unit. Corporate Governance Matters: At the Company’s 2024 Annual General Meeting held on December 18, 2024 (the “2024 AGM”), the Company’s shareholders withheld the election of one nominee, Ms. Janet Grove, from being appointed as a member of the Company’s Board of Directors (the “Board”), in accordance with the Company’s Majority Voting Policy. As a result, Ms. Grove offered her resignation to the Board, and the Company’s Nominating & Governance Committee, in accordance with the Majority Voting Policy, considered her resignation and ultimately recommended to the Board to accept Ms. Grove’s resignation. On February 10, 2024, the Board elected to accept Ms. Grove’s resignation. The Board intends to initiate a search for an independent director to replace Ms. Grove as soon as reasonably practicable. In the interim, the Board will continue to operate with the remaining four directors, and each committee of the Board will be comprised of the three independent directors who were re-appointed for directorship at the 2024 AGM. The Board Chair, Mr. Andy Hull will assume the role of Chair of the Nominating & Governance Committee. Mr. Andy Hull commented, “On behalf of the Board and management of the Company, I would like to extend our sincere gratitude to Janet for her dedication and valuable stewardship over the past three years. We are grateful for her service and wish her continued success in all her future endeavors.” Table 1. CONDENSED CONSOLIDATED BALANCE SHEETSExpressed in U.S. Dollars Table 2. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITEDExpressed in U.S. Dollars Table 3. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITEDFor the Six Months ended December 31, 2024 and 2023Expressed in U.S. Dollars About InMed: InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. For more information, visit www.inmedpharma.com. Investor Contact:Colin ClancyVice President, Investor Relationsand Corporate CommunicationsT: +1 604 416 0999E: ir@inmedpharma.com Cautionary Note Regarding Forward-Looking Information: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “potential”, “possible”, “would” and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about; the efficacy of INM-901, INM-901’s ability to treat Alzheimer’s, marketability and uses for INM-901, the results of further studies into INM-901 and acceleration of the development of InMed’s Alzheimer’s program; the efficacy of INM-089, INM-089’s ability to treat AMD, marketability and uses for INM-089, the results of further studies into INM-089 and the further development of InMed’s AMD program; potential to improve margins over time; expectations that the Company’s cash will be sufficient to fund its planned operating expenses and capital expenditures requirements to the end of the second quarter of calendar year 2025. Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K, in Item 1A. of the Quarterly Report for the period ended December 31, 2024, and other filings with the Securities and Exchange Commission on www.sec.gov. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/240646

Pharmaceutical INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs Manufacturing BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing Investors News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Corporate Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Learn INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Pharmaceutical INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs Manufacturing BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing Investors News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Corporate Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Learn INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact INM-089 IVT formulation selected for continued development Demonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and a significant safety margin Dose ranging studies completed Vancouver, British Columbia–(Newsfile Corp. – February 3, 2025) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the selection of an intravitreal (‘IVT’) formulation for INM-089 as a drug candidate to be utilized in the Company’s ongoing development program targeting the treatment of dry age-related macular degeneration (‘AMD’). Michael Woudenberg, InMed’s Chief Operating Officer and Senior Vice President of Chemistry, Manufacturing, and Controls, commented, “We are encouraged by the recent data demonstrating that INM-089 can be successfully delivered as an IVT formulation, offering several advantages for the continued development of this compound in the treatment of dry AMD. The supporting data generated through the IVT formulation underscores its potential as an effective therapeutic approach for this challenging condition.” InMed’s proprietary IVT formulation, combined with the INM-089 active pharmaceutical ingredient (‘API’), has been successfully delivered to the targeted area of the eye in preclinical studies in doses of up to 10 times the calculated safety margin relative to the therapeutic dose level. This INM-089 IVT formulation will be used in the next stages of preclinical studies, including GLP-enabling studies and subsequent stages of clinical development. Additionally, InMed has recently completed a series of dose-ranging in vivo studies. The information from the dose-ranging study will guide us in selecting the appropriate doses for the pivotal preclinical toxicology studies. Intravitreal injection has been the established method for the effective delivery of drugs to the back of the eye and remains the standard of care among retinal specialists. Topical formulations, such as eye drops, face significant challenges in delivering highly lipophilic drugs to this target tissue because the complex anatomy and protective barriers of the eye hinder effective drug permeation. About AMD and need for new treatment options AMD is a common progressive eye disease affecting the macula, or back of the eye, and impedes one’s central vision. An estimated 196 million people worldwide live with AMD. Dry AMD is the most common form, accounting for an estimated 80% of AMD cases. Until recently, there were no treatments for this prevalent disease. Two new treatments have been approved for late-stage dry AMD, also known as geographic atrophy (‘GA’). There remains a major unmet medical need for dry AMD, which impacts an estimated 12.6% of Americans aged 40+. INM-089: A promising drug candidate for Dry AMD INM-089 is a small molecule drug candidate in development for the treatment of AMD. Preclinical studies of INM-089 demonstrated significant functional and pathological improvements in a dry AMD disease study model. Results from studies demonstrate that INM-089: provides neuroprotection of photoreceptors and improves photoreceptor function; improves the integrity of the retinal pigment epithelium; reduces extracellular auto fluorescent deposits, a hallmark of dry AMD; preserves retinal function in the back of the eye; as well as improves thickness of “outer nuclear layer” of the retina where photoreceptors are located. To learn more about InMed’s INM-089 Program in the treatment of, please visit our website: https://www.inmedpharma.com/pharmaceutical/inm-089-for-age-related-macular-degeneration/ About InMed: InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. For more information, visit www.inmedpharma.com. Investor Contact: Colin Clancy Vice President, Investor Relations and Corporate Communications T: +1 604 416 0999 E: ir@inmedpharma.com Cautionary Note Regarding Forward-Looking Information: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “potential”, “possible”, “would” and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: the efficacy of INM-089; INM-089’s ability to treat AMD; marketability and uses for INM-089; the results of further studies into INM-089 and the further development of InMed’s AMD program; and, developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs. Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239355

Pharmaceutical INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs Manufacturing BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing Investors News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Corporate Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Learn INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Pharmaceutical INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs Manufacturing BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing Investors News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Corporate Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Learn INM-901 for Alzheimer’s Disease INM-089 for Age-related Macular Degeneration INM-755 for Epidermolysis Bullosa INM-088 for Glaucoma Novel Analogs BayMedica – Rare Cannabinoid Ingredients Cannabinoid Manufacturing Expertise IntegraSyn™ Cannabinoid Manufacturing News Releases Events Stock Information Corporate Governance Financials & AGM Materials Filings Presentations Media and Videos Investor Contact Management Board of Directors Scientific Advisors Partners and Collaborators Careers Contact Marks the first jurisdictional issuance of an international patent for a family of novel small molecule compounds Patent covers novel analog compounds for therapeutic applications in pain, glaucoma, inflammatory disease, anxiety, and a variety of neurological conditions including Parkinson’s disease, Alzheimer’s disease and dementia Patent also protects the methods of preparation of the compounds Marks the first jurisdictional issuance of an international patent for a family of novel small molecule compounds Patent covers novel analog compounds for therapeutic applications in pain, glaucoma, inflammatory disease, anxiety, and a variety of neurological conditions including Parkinson’s disease, Alzheimer’s disease and dementia Patent also protects the methods of preparation of the compounds Vancouver, British Columbia–(Newsfile Corp. – January 22, 2025) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces it has been granted an international Patent Cooperation Treaty (‘PCT’) patent in the first of several jurisdictions where the patent has been filed. Titled “Cannabinoid analogs and methods for their preparation“, this patent protects the use of several proprietary small molecule compounds and methods of their preparation, including the drug candidates screened for InMed’s Alzheimer’s disease and dry age-related macular degeneration programs. This Patent No. 417531 (Application No. MX/a/2021/005026) has been issued in Mexico and holds a 20-year term. The initial jurisdictional issuance of this important patent strengthens InMed’s intellectual property portfolio, ensuring the protection of innovative cannabinoid analogs designed for diverse therapeutic applications, including neurological disorders, behavioral conditions, inflammation, and other medical needs. The PCT patent further protects InMed’s production methods of its novel pharmaceutical drug development candidates utilizing modern biopharmaceutical manufacturing approaches. The international PCT application has been filed in, and is awaiting issuance from, several additional jurisdictions including the U.S., Europe, Japan and others. InMed’s President and CEO, Eric A. Adams, said, “We are pleased with this initial issuance of a key PCT patent for our proprietary small molecule drug development candidates. Our innovation includes an extensive library of novel small molecules aimed at targeting specific pharmacological properties for therapeutic application. This has led to the development of promising, novel drug candidates for Alzheimer’s disease and age-related macular degeneration.” He added, “The issuance underscores our commitment to securing the long-term intellectual property protection of our research and development efforts. We remain focused on expanding our patent portfolio to protect our novel drug candidates, methods of manufacturing these drugs, how they are formulated and how they are used to support the development of new treatments for diseases with high unmet medical needs.” InMed has a total of 14 patent families covering compositions, formulations, manufacturing processes and methods of use. Summary of Granted Patents (to date): About InMed: InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary small molecule drug candidates. For more information, visit www.inmedpharma.com. Investor Contact: Colin Clancy Vice President, Investor Relations and Corporate Communications T: +1 604 416 0999 E: IR@inmedpharma.com Cautionary Note Regarding Forward-Looking Information: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “potential”, “possible”, “would” and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: pursuing new chemical entity patents on the drug candidates for both its INM-901 program in Alzheimer’s disease and INM-089 in dry Age-related Macular Degeneration; continuing to build a patent portfolio to protect of composition of matter, formulations, manufacturing processes and methods of use. Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/238045